Citadel Advisors’s Vivos Therapeutics VVOS Stock Holding History

Citadel Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16	Closed	-$136	–	15315
2023 Q1	$136	Sell	16 -120	-88%	-$2.63K	﹤0.01%	14570
2022 Q4	$1.37K	Buy	+136	New	+$1.99K	﹤0.01%	14482
2022 Q1	–	Sell	-1,636	Closed	-$92K	–	14681
2021 Q4	$92K	Sell	1,636 -60	-4%	-$4.83K	﹤0.01%	12798
2021 Q3	$171K	Buy	+1,696	New	+$178K	﹤0.01%	12201

Other funds holding VVOS

SWIG

Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's VVOS Position: Q1 2023 in Review

Citadel Advisors sold out of Vivos Therapeutics (VVOS) in Q1 2023, closing a stake of 1,408 shares — an estimated $30.8K sold.

Citadel Advisors first reported a position in VVOS in Q1 2021 and held it in 5 quarters. The position peaked at $320K in Q3 2021. 30 funds tracked by Wall St. Rank hold VVOS as of Q1 2023.

Citadel Advisors reported no remaining Vivos Therapeutics position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 1,408 Vivos Therapeutics shares in Q1 2023, an estimated $30.8K.
Citadel Advisors first reported a position in Vivos Therapeutics in Q1 2021 and held it in 5 quarters.
Citadel Advisors's Vivos Therapeutics position peaked at $320K in Q3 2021.
30 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.